Showing results (41-50 of 384) with videos related to
Sort By:
Pageof 39
Urology|August 10, 2010
Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosisFadi Brimo, Alan W Partin, Jonathan I EpsteinThe Journal of Urology|July 20, 2002
Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. rangeAlexander Haese, Robert T Dworschack, Alan W PartinReviews in Urology|April 25, 2009
Robotic image-guided needle interventions of the prostatePierre C Mozer, Alan W Partin, Dan StoianoviciJournal of the National Cancer Institute|July 16, 2013
Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imagingDanil V Makarov, Stacy Loeb, David Ulmert, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 10, 2025
Fertility counseling in early-onset colorectal cancer and the impact of patient characteristicsChengwei Peng, Dalia Littman, Lena Masri, et al.The Journal of Urology|March 7, 2016
How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United StatesStacy Loeb, Dawn Walter, Caitlin Curnyn, et al.The Journal of Urology|May 21, 2010
Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomyStacy Loeb, Danil V Makarov, Edward M Schaeffer, et al.The Journal of Urology|October 17, 2012
Centralization of radical prostatectomy in the United StatesChristopher B Anderson, David F Penson, Shenghua Ni, et al.The Journal of Urology|September 21, 2010
Patient centered outcomes in prostate cancer treatment: predictors of satisfaction up to 2 years after open radical retropubic prostatectomyNitya E Abraham, Danil V Makarov, Juliana Laze, et al.European Urology|July 5, 2014
Five-year nationwide follow-up study of active surveillance for prostate cancerStacy Loeb, Yasin Folkvaljon, Danil V Makarov, et al.Pageof 39